Radiopharm Theranostics Limited American Depositary Shares

PINK:RADX USA Biotechnology
Market Cap
$37.13 Million
Market Cap Rank
#22364 Global
#7920 in USA
Share Price
$4.71
Change (1 day)
-9.25%
52-Week Range
$4.68 - $5.72
All Time High
$5.72
About

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more

Radiopharm Theranostics Limited American Depositary Shares (RADX) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of December 2024: -0.168x

Based on the latest financial reports, Radiopharm Theranostics Limited American Depositary Shares (RADX) has a cash flow conversion efficiency ratio of -0.168x as of December 2024.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.74 Million) by net assets ($52.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Radiopharm Theranostics Limited American Depositary Shares - Cash Flow Conversion Efficiency Trend (2022–2025)

This chart illustrates how Radiopharm Theranostics Limited American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Radiopharm Theranostics Limited American Depositary Shares Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Radiopharm Theranostics Limited American Depositary Shares ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Radiopharm Theranostics Limited American Depositary Shares (2022–2025)

The table below shows the annual cash flow conversion efficiency of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2025.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 $42.87 Million $-36.65 Million -0.855x -1.76%
2024-06-30 $27.35 Million $-22.98 Million -0.840x -65.01%
2023-06-30 $45.58 Million $-23.20 Million -0.509x -223.23%
2022-06-30 $62.96 Million $-9.92 Million -0.157x --